spacer
home > white papers > Recommendations for Implementing Assessment Criteria Guidelines in Lymphoma and Chronic Lymphocytic Leukemia Clinical Trials - Perceptive Informatics
WHITE PAPERS
logo_Perceptive2.jpg

Perceptive Informatics

phone +1.781.487.9900
web http://www.perceptive.com
email 195 West Street, Waltham, MA 02451, USA

Recommendations for Implementing Assessment Criteria Guidelines in Lymphoma and Chronic Lymphocytic Leukemia Clinical Trials

Standardized assessment criteria are becoming increasingly important in obtaining valid outcomes in oncology clinical trials. While standardized criteria encourage a more uniform approach to assessing clinical trial data, they are often subject to the interpretation of the user. These differences in interpretation, while seemingly minor, can have a major impact on assessments. The most commonly used standardized criteria for lymphoma have been no exception. Differences such as minimum new lesion size, lymph node normalization size requirements, inclusion of extranodal lesions and assessment of organomegaly can have a profound effect on overall response. Additionally, heightened scrutiny of the assessment criteria used in a given protocol can lead to questions about a drug’s efficacy if not applied correctly according to regulators’ interpretation.
Recommendations for Implementing Assessment Criteria Guidelines in Lymphoma and Chronic Lymphocytic Leukemia Clinical Trials
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Countdown to the UK’s leading production line event begins

In light of Nick Peters’, author of the Annual Manufacturing report 2018, comment that “UK manufacturing has come a long way in recent years, as we have seen from their stellar performance in 2017,” it’s no surprise that the PPMA Show is gearing up for its biggest show to date when it returns to the NEC, Birmingham, between 25-27 September 2018.
More info >>


White Papers

Translating Cancer Genomics Into A Personalised Approach For Cancer Patients

PRA Health Sciences (PRA)

Over the past few decades, the approach to prevention, diagnosis and treatment of cancer has radically shifted from organ-based to morphology-based and most recently, to genetics-based. Personalized or precision medicine (tailoring a treatment for a patient’s particular disease at a precise time point) is being performed every day at different levels in the clinical setting.
More info >>


Industry Events

BioProcess International West

19-22 March 2018,

BioProcess International West (BPI West) is the leading phase-based bioprocessing event for advancing promising biologics towards commercial success.  Join 850+ global scientists and key decision makers at our upcoming meeting, held March 19-22, 2018 in San Francisco, CA. 
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement